GET AHEAD OF AV FISTULA RESTENOSIS1

IN.PACT™ AV
Drug-Coated Balloon (DCB)
Watch the Video

56% FEWER INTERVENTIONS1 MORE OF WHAT MATTERS

The IN.PACT AV DCB has been demonstrated superior to PTA in increasing patency and prolonging time between interventions.1

View Product Details
Need image

PROACTIVE APPROACH

IN.PACT AV DCB treats the cause — not just the symptoms of fistula stenosis — enabling you to get ahead of restenosis and go longer between interventions.1

Fewer is Better

By enabling dramatically fewer AV fistula interventions,1 the IN.PACT AV DCB can make a real impact ― clinically, financially,2 and emotionally.

Hear from Dominick ―
a patient story.

COME SEE US

Visit us at upcoming events and learn about other products in the Medtronic Peripheral portfolio.

Conference Information

CONTACT US

Request more information about IN.PACT AV or any other product in our Peripheral portfolio.

SUBMIT A REQUEST
1

Results from the IN.PACT™ AV Access Clinical Trial found in the IN.PACT™ AV drug-coated balloon (DCB) Instructions For Use (IFU).

*In an AV DCB study.

2

Medicare Costs Associated with Arteriovenous Fistulas Among US Hemodialysis Patients, Thamer et al., AJKD, March 2018 ; Patients who initiated HD with a catheter.

Target Lesion Primary Patency Rate based on KM estimates: Defined as freedom from clinically driven target lesion revascularization (CD-TLR) or access circuit thrombosis calculated at 180 days.

Access Circuit Primary Patency based on KM estimates: Defined as freedom from re-intervention in the access circuit or access circuit thrombosis calculated at 180 days.

Reduction in reinterventions: Defined as the number of interventions required to maintain target lesion primary patency calculated at 210 days.